-
TR-1: Standard form for notification of major holdings
TR-1: Standard form for notification of major holdings from Lanstead Capital Investors LP To download form Click here
-
Chairman’s Open Letter to Shareholders
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, outlines below an open letter to shareholders from the Chairman, Tim McCarthy. This follows on from this week’s announcement, confirming that both resolutions proposed at the General meeting held on Tuesday 7 April 2026, were approved by Shareholders. Dear Shareholders I wanted to take this…
-
Result of General Meeting and TVR – Resolutions Approved
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that both resolutions proposed at the General meeting held earlier today were approved by Shareholders. This is further to its Fundraising announcement published on 17 March 2026 at 7:00 a.m. (the “Fundraising RNS“) and the WRAP Retail Offer announcement published on 17…
-
P140 Program Update patent progress |new supporting data | scientific publication in preparation
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to provide an update on its auto-immune technology platform program, P140. The Company has received a first Combined Search and Examination Report (“CSER”) in relation to its United Kingdom patent application for P140, filed in September 2025. The supportive response is…
-
Result of WRAP Retail Offer and TVR
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, further to its Fundraising announcement published on 17 March 2026 at 7:00 a.m. (the “Fundraising RNS“) and the WRAP Retail Offer announcement published on 17 March 2026 at 7:01 a.m. (the “WRAP RNS“), announces the result of the WRAP Retail Offer and provide an update on…
-
IMC presentation
IMMUPHARMA PLC – Corporate Update 20 March 2026 ImmuPharma PLC (IMM@AIM) provided an investor update outlining its strategic funding decision, pipeline progress, and growth strategy, reaffirming that its lead asset P140 remains the core value driver with ongoing licensing discussions and strong scientific validation supporting potential deals in 2026. The company highlighted continued progress on…
-
Publication of Circular
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces thatfurther to its ‘Fundraising’ announcement, published on 17 March 2026 at 7:00 a.m. (the “FundraisingRNS”), a circular convening a General Meeting has today been sent to shareholders.The General Meeting is scheduled to be held at 11.00 a.m. on 7 April 2026, at the offices…
-
ImmuPharma to present live on ‘Investor Meet Company’ platform Friday 20 March 2026 @ 12:00 (GMT)
ImmuPharma PLC (LSE AIM:), the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics is pleased to announce that ImmuPharma’s Tim McCarthy, CEO, Dr Sébastien Goudreau, CSO, and Dr Tim Franklin, COO, will provide a live presentation relating to the Company’s announcement, released on Tuesday 17 March 2026, titled: P140 Update – remains on track…
-
Proactive
ImmuPharma CEO on P140 progress and expanded pipeline with Kapiglucagon 17 March 2026 ImmuPharma PLC (AIM:IMM, FRA:25I) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company’s latest developments, including progress on its lead asset P140, a newly accelerated program for Kapiglucagon, and recent fundraising activity. – March 2026
-
WRAP Retail Offer for up to £1.5 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION…
